Merck (MRK) Announces FDA Granted Priority Review to its sBLA for KEYTRUDA for Treatment of Patients with Advanced Hepatocellular Carcinoma

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug ...